BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom.

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain.

Foshan Hanfang Traditional Chinese Medicine Hospital Co., Ltd., established on 2016-11-17, Business scope includes licensed projects:medical service;Health food sales;food business;food business(Selling prepackaged food);Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Health Consulting Services(Does not include medical services);Fresh Fruit Wholesale;Fresh Fruit Retail;Fresh Vegetable Retail;Wholesale Fresh Vegetables;Daily necessities sales;Cosmetics Wholesale;Cosmetics Retail;Sales of Class I Medical Devices;Sales of Class II Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden. In 2009, Biovitrum merged with [Swedish Orphan](/organization/swedish-orphan), and the combined company has subsequently been rebranded as Swedish Orphan Biovitrum.

Sunshine Lake Pharma Co. Ltd., a subsidiary of Shenzhen Dongyangguang Industry Co., Ltd., is a Chinese company. The firm manufactures and supplies pharmaceutical ingredients and drugs. Wen Jia Li has been the CEO since 2021. On December 23, 2022 Shenzhen Dongyangguang Industry Co., Ltd. acquired Sunshine Lake Pharma Co. Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. for $330.99 million.

Manufactures pharmaceuticals

Provides research and development services for pharmaceutical preparations

Guangdong Cyber ​​Technology Co., Ltd., established on 2016-03-01, Business scope includes computer software,the hardware,Network equipment design, development and sales;website design,e-commerce,Communication system development and integration,Automation control system development and integration;Technical services for automation engineering;Research project management,consult,review;industry,Business Incubation Base;Enterprise Management Information Consulting,Intellectual Property Services;R&D and sales of energy-saving and environmental protection products;Business Consulting;Health Consulting Services;Domestic Trade;Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

Faron Pharmaceuticals Oy operates as a clinical stage biopharmaceutical company. It develops novel treatments for medical conditions with significant unmet needs caused by dysfunction of immune system. The firm currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Its Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. The company was founded by Juho Markku Jalkanen, Sirpa Tuulikki Jalkanen, Matti Esa Manner, Juha Peltola, Marko Salmi, Katriina Peltola and Maija-Leena Hollmen in 2003 and is headquartered in Turku, Finland.

Shanghai Ennovabio Pharmaceuticals Co. Ltd. is a private company headquartered in Shanghai, China, that manufactures pharmaceutical products.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Beijing Institute of Technology Genyuan Technology Co., Ltd., established on 2003-09-02, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;Natural science research and experimental development;Conference Services;Undertake exhibition and display activities;design,make,acting,Place an ad;business management;selling computers,Software and Auxiliary Equipment,Equipment,hardware,AC;Rental machinery and equipment(Car rental not included);Import and export,Technology Import and Export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and redox control have been well characterized.